International Bio Immune Systems Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

International Bio Immune Systems General Information

Description

Provider of bio-pharmaceutical research services. The company operates as a platform for immunodiagnostic and therapeutic antibodies along with their associated tumor associated antigens to develop new drugs that may benefit cancer patients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 225 Community Drive
  • Great Neck, NY 11021
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

International Bio Immune Systems Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore International Bio Immune Systems‘s full profile, request access.

Request a free trial

International Bio Immune Systems Patents

International Bio Immune Systems Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2421070-A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma Abandoned 01-Sep-2000 00000000000
US-20040136997-A1 Bind to a cell membrane antigen found on squamous cell carcinomas but show no or limited reactivity with normal cells or other types of cancers Granted 01-Sep-2000 00000000000 0
US-7491801-B2 Bind to a cell membrane antigen found on squamous cell carcinomas but show no or limited reactivity with normal cells or other types of cancers Expired - Fee Related 01-Sep-2000 00000000000
AU-8843601-A The identification and development of specific monoclonal antibodies to squamouscell carcinoma Withdrawn 01-Sep-2000 00000000000
EP-1320551-A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma Withdrawn 01-Sep-2000 C07K16/3007 0

International Bio Immune Systems Executive Team (1)

Name Title Board Seat Contact Info
Leslie Stern Principal
To view International Bio Immune Systems’s complete executive team members history, request access »